{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T01:19:41Z","timestamp":1782436781245,"version":"3.54.5"},"reference-count":30,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"unspecified","delay-in-days":40,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Epidemiol. Infect."],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:p>Much of our current understanding about novel coronavirus disease 2019 (COVID-19) comes from hospitalised patients. However, the spectrum of mild and subclinical disease has implications for population-level screening and control. Forty-nine participants were recruited from a group of 99 adults repatriated from a cruise ship with a high incidence of COVID-19. Respiratory and rectal swabs were tested by polymerase chain reaction (PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Sera were tested for anti-SARS-CoV-2 antibodies by enzyme-linked immunosorbent assay (ELISA) and microneutralisation assay. Symptoms, viral shedding and antibody response were examined. Forty-five participants (92%) were considered cases based on either positive PCR or positive ELISA for immunoglobulin G. Forty-two percent of cases were asymptomatic. Only 15% of symptomatic cases reported fever. Serial respiratory and rectal swabs were positive for 10% and 5% of participants respectively about 3 weeks after median symptom onset. Cycle threshold values were high (range 31\u201345). Attempts to isolate live virus were unsuccessful. The presence of symptoms was not associated with demographics, comorbidities or antibody response. In closed settings, incidence of COVID-19 could be almost double that suggested by symptom-based screening. Serology may be useful in diagnosis of mild disease and in aiding public health investigations.<\/jats:p>","DOI":"10.1017\/s0950268821000315","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T09:19:08Z","timestamp":1612948748000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":12,"title":["Symptoms and laboratory manifestations of mild COVID-19 in a repatriated cruise ship cohort"],"prefix":"10.1017","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-0428","authenticated-orcid":false,"given":"C. R.","family":"Bailie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3754-2642","authenticated-orcid":false,"given":"F.","family":"Mordant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Alpren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Druce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Subbarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Catton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"van Diemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. G.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"key":"S0950268821000315_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30243-7"},{"key":"S0950268821000315_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30083-2"},{"key":"S0950268821000315_ref16","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.18.2000603"},{"key":"S0950268821000315_ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2196-x"},{"key":"S0950268821000315_ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0817-4"},{"key":"S0950268821000315_ref27","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.10.2000180"},{"key":"S0950268821000315_ref30","unstructured":"30. Davies, ABB (2020) Ruby Princess: battle begins to hold someone accountable for cruise ship coronavirus debacle. The Guardian, Australia edition 2020; 10 April. Available at https:\/\/www.theguardian.com\/business\/2020\/apr\/10\/ruby-princess-battle-begins-to-hold-so."},{"key":"S0950268821000315_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30232-2"},{"key":"S0950268821000315_ref15","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvaa120"},{"key":"S0950268821000315_ref17","first-page":"13","article-title":"Diagnostic performance of COVID-19 serology assays","volume":"42","author":"Zainol Rashid","year":"2020","journal-title":"Malaysian Journal of Pathology"},{"key":"S0950268821000315_ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30322-4"},{"key":"S0950268821000315_ref23","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-215091"},{"key":"S0950268821000315_ref14","article-title":"Role of serology in the COVID-19 pandemic","author":"Stowell","year":"2020","journal-title":"Clinical Infectious Diseases"},{"key":"S0950268821000315_ref3","doi-asserted-by":"publisher","DOI":"10.1177\/0145561320920762"},{"key":"S0950268821000315_ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0869-5"},{"key":"S0950268821000315_ref29","unstructured":"29. Korea Centers for Disease Control and Prevention \u2013 Division of Risk assessment and International cooperation. Press release: findings from investigation and analysis of re-positive cases (2020). Available at https:\/\/www.cdc.go.kr\/board\/board.es?mid=&bid=0030&act=view&list_no=367267&nPage=1 (Accessed 20 June 2020)."},{"key":"S0950268821000315_ref8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa351"},{"key":"S0950268821000315_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.041"},{"key":"S0950268821000315_ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2013020"},{"key":"S0950268821000315_ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002032"},{"key":"S0950268821000315_ref24","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50569"},{"key":"S0950268821000315_ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-020-05965-1"},{"key":"S0950268821000315_ref26","unstructured":"26. EUROIMMUN Medizinische Labordiagnostika AG (2020) Anti-SARS-CoV-2 ELISA (IgA) Instruction for use. Version: 2020-04-22."},{"key":"S0950268821000315_ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0822-7"},{"key":"S0950268821000315_ref18","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1756699"},{"key":"S0950268821000315_ref28","doi-asserted-by":"publisher","DOI":"10.1186\/s41182-020-00201-2"},{"key":"S0950268821000315_ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0965-6"},{"key":"S0950268821000315_ref25","unstructured":"25. EUROIMMUN Medizinische Labordiagnostika AG (2020) Anti-SARS-CoV-2 ELISA (IgG) Instruction for use. Version: 2020-04-22."},{"key":"S0950268821000315_ref4","first-page":"501","article-title":"Gender differences in the frequency of gastrointestinal symptoms and olfactory or taste disorders among 1,942 non-hospitalized patients with COVID-19","volume":"130","author":"Sierpiski","year":"2020","journal-title":"Polish Archives of Internal Medicine"},{"key":"S0950268821000315_ref6","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000664"}],"container-title":["Epidemiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0950268821000315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T03:58:05Z","timestamp":1613966285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0950268821000315\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":30,"alternative-id":["S0950268821000315"],"URL":"https:\/\/doi.org\/10.1017\/s0950268821000315","relation":{},"ISSN":["0950-2688","1469-4409"],"issn-type":[{"value":"0950-2688","type":"print"},{"value":"1469-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Copyright \u00a9 The Author(s), 2021. Published by Cambridge University Press","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e44"}}